Viridian Net Tangible Assets from 2010 to 2026
| VRDN Stock | USD 27.90 0.85 2.96% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 290.9 M | Current Value 305.4 M | Quarterly Volatility 147.1 M |
Check Viridian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 3.7 M or Selling General Administrative of 73.8 M, as well as many indicators such as Price To Sales Ratio of 4.1 K, Dividend Yield of 0.0014 or PTB Ratio of 3.81. Viridian financial statements analysis is a perfect complement when working with Viridian Therapeutics Valuation or Volatility modules.
Viridian | Net Tangible Assets | Build AI portfolio with Viridian Stock |
Evaluating Viridian Therapeutics's Net Tangible Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Viridian Therapeutics's fundamental strength.
Latest Viridian Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Viridian Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Viridian Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viridian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Viridian Net Tangible Assets Regression Statistics
| Arithmetic Mean | 60,016,637 | |
| Geometric Mean | 83,956,153 | |
| Coefficient Of Variation | 245.14 | |
| Mean Deviation | 124,108,193 | |
| Median | 15,754,000 | |
| Standard Deviation | 147,125,261 | |
| Sample Variance | 21645.8T | |
| Range | 367.3M | |
| R-Value | 0.88 | |
| Mean Square Error | 5219.7T | |
| R-Squared | 0.77 | |
| Slope | 25,631,164 | |
| Total Sum of Squares | 346333.5T |
Viridian Net Tangible Assets History
About Viridian Therapeutics Financial Statements
Viridian Therapeutics investors utilize fundamental indicators, such as Net Tangible Assets, to predict how Viridian Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 290.9 M | 305.4 M |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Viridian Stock
| 0.69 | PYC | Physiomics Plc | PairCorr |
| 0.36 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.36 | ALSEN | Sensorion SA | PairCorr |
| 0.32 | ABNX | Abionyx Pharma SA | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Viridian Therapeutics Correlation against competitors. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value - what Viridian Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.